{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:00:53Z","timestamp":1777982453791,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NOVARTIS Biociencias SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06854-z","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:36:01Z","timestamp":1771490161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of vaso-occlusive crisis requiring hospitalization in sickle cell disease patients in brazil: retrospective cohort study of real-world data"],"prefix":"10.1007","volume":"105","author":[{"given":"Vanessa Maia","family":"de Almeida Barros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina","family":"Silva-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Gomes","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra F\u00e1tima Menosi","family":"Gualandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo Delfini","family":"Can\u00e7ado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"1","key":"6854_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","volume":"328","author":"PL Kavanagh","year":"2022","unstructured":"Kavanagh PL, Fasipe TA, Wun T (2022) Sickle cell disease. JAMA 328(1):57\u201368. https:\/\/doi.org\/10.1001\/jama.2022.10233","journal-title":"JAMA"},{"issue":"7424","key":"6854_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/bmj.327.7424.1151","volume":"327","author":"S Claster","year":"2003","unstructured":"Claster S, Vichinsky PE (2003) Managing sickle cell disease. BMJ 327(7424):1151\u20131155. https:\/\/doi.org\/10.1136\/bmj.327.7424.1151","journal-title":"BMJ"},{"issue":"8","key":"6854_CR3","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","volume":"10","author":"AM Thomson","year":"2023","unstructured":"Thomson AM et al (2023) Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol 10(8):e585\u2013e599. https:\/\/doi.org\/10.1016\/S2352-3026(23)00118-7","journal-title":"Lancet Haematol"},{"issue":"15","key":"6854_CR4","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1182\/bloodadvances.2022008938","volume":"7","author":"RD Can\u00e7ado","year":"2023","unstructured":"Can\u00e7ado RD et al (2023) Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence. Blood Adv 7(15):3783\u20133792. https:\/\/doi.org\/10.1182\/bloodadvances.2022008938","journal-title":"Blood Adv"},{"key":"6854_CR5","doi-asserted-by":"publisher","DOI":"10.1201\/9781003099062","volume-title":"Maternal-Fetal Evidence Based Guidelines","author":"V Berghella","year":"2022","unstructured":"Berghella V (2022) Maternal-Fetal Evidence Based Guidelines. CRC Press, Boca Raton. https:\/\/doi.org\/10.1201\/9781003099062"},{"issue":"9079","key":"6854_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(97)07330-3","volume":"350","author":"GR Serjeant","year":"1997","unstructured":"Serjeant GR (1997) Sickle-cell disease. Lancet 350(9079):725\u2013730. https:\/\/doi.org\/10.1016\/S0140-6736(97)07330-3","journal-title":"Lancet"},{"key":"6854_CR7","doi-asserted-by":"publisher","unstructured":"Wastnedge E et al (2018) The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health 8(2). https:\/\/doi.org\/10.7189\/jogh.08.021103","DOI":"10.7189\/jogh.08.021103"},{"issue":"4","key":"6854_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/pbc.23181","volume":"58","author":"JL Raphael","year":"2012","unstructured":"Raphael JL, Mei M, Mueller BU, Giordano T (2012) High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer 58(4):584\u2013590. https:\/\/doi.org\/10.1002\/pbc.23181","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"6854_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/13696998.2020.1813144","volume":"23","author":"NR Shah","year":"2020","unstructured":"Shah NR et al (2020) Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance \u2013 the perspective of private and public payers. J Med Econ 23(11):1345\u20131355. https:\/\/doi.org\/10.1080\/13696998.2020.1813144","journal-title":"J Med Econ"},{"issue":"1","key":"6854_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.36469\/jheor.2020.12852","volume":"7","author":"N Shah","year":"2020","unstructured":"Shah N, Bhor M, Xie L, Paulose J, Yuce H (2020) Medical resource use and costs of treating sickle Cell-related vaso-occlusive crisis episodes: a retrospective claims study. J Health Econ Outcomes Res 7(1):52\u201360. https:\/\/doi.org\/10.36469\/jheor.2020.12852","journal-title":"J Health Econ Outcomes Res"},{"issue":"4","key":"6854_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajh.25724","volume":"95","author":"MH Steinberg","year":"2020","unstructured":"Steinberg MH (2020) Treating sickle cell anemia: a new era dawns. Am J Hematol 95(4):338\u2013342. https:\/\/doi.org\/10.1002\/ajh.25724","journal-title":"Am J Hematol"},{"issue":"1","key":"6854_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prrv.2013.11.003","volume":"15","author":"SL Saraf","year":"2014","unstructured":"Saraf SL et al (2014) Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev 15(1):4\u201312. https:\/\/doi.org\/10.1016\/j.prrv.2013.11.003","journal-title":"Paediatr Respir Rev"},{"issue":"6","key":"6854_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/bjh.15462","volume":"182","author":"ABF Carneiro-Proietti","year":"2018","unstructured":"Carneiro-Proietti ABF et al (2018) Clinical and genetic ancestry profile of a large multi\u2010centre sickle cell disease cohort in Brazil. Br J Haematol 182(6):895\u2013908. https:\/\/doi.org\/10.1111\/bjh.15462","journal-title":"Br J Haematol"},{"issue":"7624","key":"6854_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624):806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD","journal-title":"BMJ"},{"issue":"1","key":"6854_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01694-7","volume":"22","author":"L Naing","year":"2022","unstructured":"Naing L, Bin Nordin R, Abdul Rahman H, Naing YT (2022) Sample size calculation for prevalence studies using Scalex and ScalaR calculators. BMC Med Res Methodol 22(1):209. https:\/\/doi.org\/10.1186\/s12874-022-01694-7","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"6854_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269703","volume":"17","author":"AC Silva-Pinto","year":"2022","unstructured":"Silva-Pinto AC et al (2022) Economic burden of sickle cell disease in Brazil. PLoS One 17(6):e0269703. https:\/\/doi.org\/10.1371\/journal.pone.0269703","journal-title":"PLoS One"},{"key":"6854_CR17","doi-asserted-by":"publisher","unstructured":"Loureiro MM, Rozenfeld S, Carvalho MS, Portugal RD (2009) Factors associated with hospital readmission in sickle cell disease. BMC Hematol 9(1). https:\/\/doi.org\/10.1186\/1471-2326-9-2","DOI":"10.1186\/1471-2326-9-2"},{"issue":"8","key":"6854_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/trf.15818","volume":"60","author":"S Kelly","year":"2020","unstructured":"Kelly S et al (2020) Blood utilization and characteristics of patients treated with chronic transfusion therapy in a large cohort of Brazilian patients with sickle cell disease. Transfusion (Paris) 60(8):1713\u20131722. https:\/\/doi.org\/10.1111\/trf.15818","journal-title":"Transfusion (Paris)"},{"issue":"1","key":"6854_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bjhh.2017.09.006","volume":"40","author":"CL de C. Lobo","year":"2018","unstructured":"de C. Lobo CL, do Nascimento EM, de Jesus LJC, de Freitas TG, Lugon JR, Ballas SK (2018) Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. Hematol Transfus Cell Ther 40(1):37\u201342. https:\/\/doi.org\/10.1016\/j.bjhh.2017.09.006","journal-title":"Hematol Transfus Cell Ther"},{"key":"6854_CR20","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.htct.2022.09.095","volume":"44","author":"B Oliveira","year":"2022","unstructured":"Oliveira B et al (2022) Clinical predictors of vaso-occlusive pain hospitalization in patients with sickle cell disease (SCD). Hematol Transfus Cell Ther 44:S57. https:\/\/doi.org\/10.1016\/j.htct.2022.09.095","journal-title":"Hematol Transfus Cell Ther"},{"issue":"9","key":"6854_CR21","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00277-022-04918-4","volume":"101","author":"EMH Padr\u00e3o","year":"2022","unstructured":"Padr\u00e3o EMH, Bustos B, Mahesh A, Fonseca GHH, Taniguchi LU (2022) Phenotypes of sickle cell intensive care admissions: an unsupervised machine learning approach in a single-center retrospective cohort. Ann Hematol 101(9):1951\u20131957. https:\/\/doi.org\/10.1007\/s00277-022-04918-4","journal-title":"Ann Hematol"},{"issue":"6","key":"6854_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/bjh.13526","volume":"170","author":"A Sobota","year":"2015","unstructured":"Sobota A, Sabharwal V, Fonebi G, Steinberg M (2015) How we prevent and manage infection in sickle cell disease. Br J Haematol 170(6):757\u2013767. https:\/\/doi.org\/10.1111\/bjh.13526","journal-title":"Br J Haematol"},{"issue":"2","key":"6854_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","volume":"123","author":"EA Manci","year":"2003","unstructured":"Manci EA et al (2003) Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123(2):359\u2013365. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04594.x","journal-title":"Br J Haematol"},{"issue":"3","key":"6854_CR24","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","volume":"76","author":"AB Payne","year":"2020","unstructured":"Payne AB et al (2020) Trends in sickle cell disease\u2013related mortality in the United States, 1979 to 2017. Ann Emerg Med 76(3):S28\u2013S36. https:\/\/doi.org\/10.1016\/j.annemergmed.2020.08.009","journal-title":"Ann Emerg Med"},{"key":"6854_CR25","first-page":"265","volume":"3","author":"GS Mach\u00edn","year":"2015","unstructured":"Mach\u00edn GS, \u00c1lvarez MI, Svarch E, Men\u00e9ndez VA, Hern\u00e1ndez PC, Sosa PO (2015) Morbidity and mortality of sickle cell anemia: thirty-six years of observational study. Rev Cubana Hematol Inmunol Hemoter 3:265\u2013276","journal-title":"Rev Cubana Hematol Inmunol Hemoter"},{"issue":"2","key":"6854_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.htct.2020.09.154","volume":"44","author":"AH Santo","year":"2022","unstructured":"Santo AH (2022) Sickle cell disease related mortality in Brazil, 2000\u20132018. Hematol Transfus Cell Ther 44(2):177\u2013185. https:\/\/doi.org\/10.1016\/j.htct.2020.09.154","journal-title":"Hematol Transfus Cell Ther"},{"issue":"9","key":"6854_CR27","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/pbc.24557","volume":"60","author":"D Hamideh","year":"2013","unstructured":"Hamideh D, Alvarez O (2013) Sickle cell disease related mortality in the united States (1999\u20132009). Pediatr Blood Cancer 60(9):1482\u20131486. https:\/\/doi.org\/10.1002\/pbc.24557","journal-title":"Pediatr Blood Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06854-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06854-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06854-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:55Z","timestamp":1776405535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06854-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6854"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06854-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7576339\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VMAB is an employee of Novartis Bioci\u00eancias SA. ACSP has participated in some advisory boards sponsored by Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}